Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 3
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 1(1)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04876651Phase 3Terminated

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Role: lead

NCT05563272Phase 2Terminated

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Role: lead

NCT06537596Phase 1Recruiting

89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma

Role: lead

All 3 trials loaded